ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

BCTXW BriaCell Therapeutics Corporation

0.47
0.0001 (0.02%)
Última actualización: 10:15:55
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
BriaCell Therapeutics Corporation BCTXW NASDAQ Warrant Capital Accionario
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.0001 0.02% 0.47 10:15:55
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.45 0.4131 0.5139 0.4699
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
03/6/202407:00GLOBEBriaCell Presents Clinical Efficacy Data at ASCO 2024
30/5/202407:00GLOBEBriaCell Initiates Patient Enrollment in First-in-Human..
28/5/202407:00GLOBEBriaCell Announces Clinical Supply Agreement with BeiGene..
24/5/202407:58EDGAR2Form SC 13D/A - General statement of acquisition of..
24/5/202407:00GLOBEBriaCell Doubles Progression-Free-Survival (PFS) and Reports..
20/5/202415:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202415:51EDGAR2Form 8-K - Current report
17/5/202415:33GLOBEBriaCell Therapeutics Announces Closing of $5.0 Million..
16/5/202416:10EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/5/202407:00GLOBEBriaCell Therapeutics Announces Pricing of $5.0 Million..
24/4/202407:00GLOBEBriaCell Announces Oral and Poster Presentations at ASCO..
10/4/202407:00GLOBEBriaCell 2024 AACR Preclinical Poster Confirms Strong..
09/4/202407:00GLOBEBriaCell Showcases Data Demonstrating Unmatched..
07/3/202407:00GLOBEBriaCell Receives and Executes Letter of Intent to Advance..
06/3/202407:00GLOBEBriaCell to Present Clinical Data in Central Nervous System..
27/2/202407:00GLOBEBriaCell Provides Update on Alleged Illegal Trading of..
07/2/202407:00GLOBEBriaCell Announces Strong Clinical Data in Breast Cancer..
06/2/202407:30GLOBEBreaking Ground in Prostate Cancer: BriaCell Announces Lead..
30/1/202421:48GLOBEBriaCell Therapeutics Corp. Announces Results of Shareholder..
04/1/202407:45GLOBEBriaCell Images Confirm Robust Anti-Tumor Activity in..
28/12/202307:55GLOBEBriaCell Reports 71% Central Nervous System Response Rate in..
20/12/202307:40GLOBEBriaCell Reports Unprecedented Preliminary Survival and..
06/12/202308:31GLOBEBriaCell Highlights Outstanding Topline Survival and..
06/12/202308:00GLOBEBriaCell 2023 SABCS Posters Confirm Activation of..
30/11/202306:00GLOBEBriaCell Records New Responder with Remarkable Improvement..
03/11/202307:31GLOBEBriaCell Reports Unprecedented Anti-Tumor Activity of its..
25/10/202308:15GLOBEBriaCell Forms Medical Advisory Board of Distinguished..
20/10/202308:15GLOBEOctober is Breast Cancer Awareness Month – BriaCell is..
18/10/202308:00GLOBEBriaCell Announces Presentations at the 2023 Society for the..
11/10/202308:10GLOBEBriaCell To Host Virtual Key Opinion Leader Event on..
04/10/202308:00GLOBEBriaCell Partners with New York Cancer & Blood Specialists..
03/10/202308:00GLOBEBriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in..
08/9/202306:00GLOBEBriaCell Reports Benchmark-Beating Patient Survival and..
31/8/202310:54GLOBEBriaCell Therapeutics Corp. Announces Closing of Plan of..
31/8/202307:21GLOBEBriaCell Accepts Letter of Intent from Weill Cornell..
25/8/202313:33GLOBEBriaCell Receives Court Approval for the Share Arrangement..
18/8/202311:21GLOBEBriaCell Therapeutics Corp. Announces Voting Results From..
16/8/202307:36GLOBEBriaCell Awarded National Cancer Institute Grant to Advance..
27/6/202307:05GLOBEFDA Approves BriaCell’s Pivotal Registrational Study Design..

Su Consulta Reciente

Delayed Upgrade Clock